Outracing 2 giant rivals, J&J touts promising PhIII Invokana data as a game-changer for kidney disease risks
In a race to expand market share against two top rivals in the diabetes field, J&J just scored one in the win column. And they’ll play it for all it’s worth in an attempt to revive flagging sales.
Researchers for the pharma giant spelled out a significant advantage for diabetics taking their SGLT2 standard bearer Invokana. In a Phase III study, the drug scored a 30% reduction in the risk of a composite of ailments that many patients face: a progression to the doubling of serum creatinine, end-stage kidney disease and renal or cardiovascular death. Just looking at ESKD — a major fear among tens of millions of diabetics, 40% of whom will go on to develop kidney disease — there was a 32% reduction in risk.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.